SCHEDULE: Alyeska Investment Group Discloses 9.99% Stake in Intelligent Bio Solutions

Alyeska Investment Group, L.P. and its affiliates have reported a 9.99% beneficial ownership stake in Intelligent Bio Solutions Inc. as of September 30, 2025.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 944,310 shares of Intelligent Bio Solutions Inc. Class A Common Stock.
• This represents 9.99% of the issuer's Class A Common Stock outstanding as of September 30, 2025.
• The reporting persons hold shared voting power and shared dispositive power over all 944,310 shares.
• The reported ownership includes 673,492 shares of Class A common stock and a limited exercisable portion of various warrants (pre-funded, Series H-1, H-2, and J Warrants).
• Due to a 9.9% beneficial ownership limitation embedded in the warrant terms, only 262,311 shares underlying the warrants are currently exercisable and included in the reported beneficial ownership.
• The percentage calculation is based on 9,452,553 outstanding shares of Ordinary Shares of the Issuer, as reported in Intelligent Bio Solutions Inc.'s Form 10-Q filed with the SEC on November 12, 2025.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by a reputable investment group like Alyeska Investment Group is generally viewed positively, indicating institutional confidence in the company. The certification that the shares were acquired in the ordinary course of business and not for control purposes also suggests a passive, long-term investment perspective.

Positives

• A significant stake (9.99%) by an institutional investment group like Alyeska Investment Group may signal confidence in Intelligent Bio Solutions Inc.'s future prospects.
• The investment group holds shared voting and dispositive power, indicating a coordinated investment strategy.

Risks

• The 9.9% beneficial ownership limitation on warrant exercise could restrict the reporting persons' ability to fully convert their warrants into common stock, potentially limiting their upside if the stock price increases significantly.
• A large institutional holder could exert influence on company decisions, which may or may not align with all shareholders' interests.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a significant ownership stake by an institutional investor. It does not provide broader industry trends or competitive analysis but highlights an investment decision within the biotechnology solutions sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near 10% stake could be seen as a positive signal, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the investment is not for control purposes.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of beneficial ownership by Alyeska Investment Group. While a significant institutional stake can be a positive signal, the filing itself does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial reports or strategic updates from Intelligent Bio Solutions Inc. to make a more informed decision, while acknowledging the institutional confidence implied by this filing.

Keywords

Intelligent Bio Solutions, Alyeska Investment Group, SEC filing, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investment, warrants, stock ownership, investment disclosure